SCHEMBL4993089

SCHEMBL4993089

CCN(CCOC)c1ccc(N/C=C2\C(=O)Nc3cc(F)ccc32)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 5/20 0.45
TGM2 P21980 1/20 0.44
KDR P35968 4/20 0.42
PRKAA1 Q13131 2/20 0.42
PRKAA2 P54646 1/20 0.42
CSF1R P07333 2/20 0.41
MDM2 Q00987 2/20 0.40
FLT3 P36888 4/20 0.39
EGFR P00533 1/20 0.37
RET P07949 2/20 0.37
AURKB Q96GD4 2/20 0.36
AURKA O14965 1/20 0.36
PDGFRA P16234 1/20 0.36
AURKC Q9UQB9 1/20 0.36
CCNE1 P24864 2/20 0.35
CDK2 P24941 2/20 0.35
CCNE2 O96020 1/20 0.35
PLK4 O00444 1/20 0.35
DCLK1 O15075 1/20 0.35
PDPK1 O15530 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4993094 1.00 PDGFRB (0.45) PDGFRBTGM2KDRPRKAA1PRKAA2
SCHEMBL4998735 0.93 PDGFRB (0.44) PDGFRBTGM2KDRPRKAA1PRKAA2
SCHEMBL4998737 0.93 PDGFRB (0.44) PDGFRBTGM2KDRPRKAA1PRKAA2
SCHEMBL4999347 0.92 RET (0.43) PDGFRBKDRPRKAA1PRKAA2CSF1R
SCHEMBL4999340 0.92 RET (0.43) PDGFRBKDRPRKAA1PRKAA2CSF1R
SCHEMBL4994636 0.90 PDGFRB (0.52) PDGFRBTGM2KDRPRKAA1PRKAA2
SCHEMBL4994637 0.90 PDGFRB (0.52) PDGFRBTGM2KDRPRKAA1PRKAA2
SCHEMBL4991006 0.88 PDGFRB (0.49) PDGFRBTGM2KDRPRKAA1PRKAA2
SCHEMBL4991014 0.88 PDGFRB (0.49) PDGFRBTGM2KDRPRKAA1PRKAA2
SCHEMBL4995679 0.88 PDGFRB (0.47) PDGFRBTGM2KDRPRKAA1PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
EP-1430048-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS Allergan, Inc. (US) 2004-06-23 EP disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
WO-2003027102-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 PDGFRB 307/4885TGM2 3215/4885KDR 256/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 PDGFRB 307/4885TGM2 3215/4885KDR 256/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 PDGFRB 307/4885TGM2 3215/4885KDR 256/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 PDGFRB 307/4885TGM2 3215/4885KDR 256/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 PDGFRB 307/4885TGM2 3215/4885KDR 256/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 PDGFRB 307/4885TGM2 3215/4885KDR 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.